How many stocks are there of Haemonetics?
The current number of stocks of Haemonetics is 51.4 M undefined.
Haemonetics Stocks 2024
Haemonetics Stocks
51.4 M
Ticker
HAE
ISIN
US4050241003
WKN
881782
In 2024, Haemonetics had 51.4 M outstanding stocks, a -0.01% change from the 51.4 M stocks in the previous year.
The Haemonetics Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2028e | 51.4 |
| 2027e | 51.4 |
| 2026e | 51.4 |
| 2025e | 51.4 |
| 2024 | 51.4 |
| 2023 | 51.4 |
| 2022 | 51.4 |
| 2021 | 51.3 |
| 2020 | 51.8 |
| 2019 | 52.9 |
| 2018 | 53.5 |
| 2017 | 51.5 |
| 2016 | 50.9 |
| 2015 | 52.1 |
| 2014 | 52.4 |
| 2013 | 52.3 |
| 2012 | 51.6 |
| 2011 | 51.2 |
| 2010 | 52.1 |
| 2009 | 52.3 |
| 2008 | 53.5 |
| 2007 | 55.3 |
| 2006 | 54.9 |
| 2005 | 52.3 |
Haemonetics shares outstanding US4050241003 · 881782
The number of shares was Haemonetics in 2023 — This indicates how many shares 51.4 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Haemonetics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Haemonetics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Haemonetics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Haemonetics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2005 | 52.3 M Aktien |
| 2006 | 54.9 M Aktien |
| 2007 | 55.3 M Aktien |
| 2008 | 53.5 M Aktien |
| 2009 | 52.3 M Aktien |
| 2010 | 52.1 M Aktien |
| 2011 | 51.2 M Aktien |
| 2012 | 51.6 M Aktien |
| 2013 | 52.3 M Aktien |
| 2014 | 52.4 M Aktien |
| 2015 | 52.1 M Aktien |
| 2016 | 50.9 M Aktien |
| 2017 | 51.5 M Aktien |
| 2018 | 53.5 M Aktien |
| 2019 | 52.9 M Aktien |
| 2020 | 51.8 M Aktien |
| 2021 | 51.3 M Aktien |
| 2022 | 51.4 M Aktien |
| 2023 | 51.4 M Aktien |
| 2024 | 51.4 M Aktien |
| 2025e | 51.4 M Aktien |
| 2026e | 51.4 M Aktien |
| 2027e | 51.4 M Aktien |
| 2028e | 51.4 M Aktien |
Haemonetics Aktienanalyse
What does Haemonetics do?
Haemonetics Corp is a leading provider of blood processing and transfusion products. The company was founded in 1971 by Dr. Jack Latham to create a better solution for the storage and transfer of blood products. Since then, the company has become a major provider of products and services for the blood transfusion industry. Haemonetics' business model is focused on the development, manufacturing, and marketing of products and devices for blood transfusion. The company offers a wide range of products and services, including blood processing systems, blood collection and maintenance devices, software solutions, blood components, and related accessories. In recent years, Haemonetics has dedicated itself to diversifying its offerings. While still focusing on the blood transfusion industry, the company has also expanded into other areas, such as the treatment of patients with blood disorders and the development of devices for cell therapy. Haemonetics is divided into various business segments, including Blood Management Solutions, Diagnostic Solutions, and Haemonetics Software Solutions. The Blood Management Solutions segment includes a range of products, including blood collection and storage devices, centrifuges, and hematocrit systems. Diagnostic Solutions provides diagnostic tests for blood disorders, including tests for coagulation disorders and thrombophilia. Haemonetics Software Solutions offers software solutions for the blood transfusion industry, including systems for automated processing and storage of blood products, as well as systems for automatic inventory management. Haemonetics' products also include devices for freezing blood products and for processing blood components. These devices help ensure that blood products are stored at optimal temperatures and conditions to ensure their effectiveness and usability for the patient. Another important area of Haemonetics' business is the development of devices for cell therapy. The company works closely with research institutes and biotech companies to develop innovative technologies for cell therapy. This includes the development of devices for the isolation and purification of stem cells that can be used for the treatment of cancer and other diseases. Haemonetics Corp has made a name for itself in the blood transfusion industry and continues to focus on innovation and diversification to fully utilize the potential of the company and its products. With a wide range of products and services, a strong commitment to research and development, and an unwavering focus on the needs of patients and healthcare providers, Haemonetics is well positioned to continue growing and expanding in the future. Haemonetics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Haemonetics's Shares Outstanding
Haemonetics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Haemonetics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Haemonetics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Haemonetics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Haemonetics stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Haemonetics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Haemonetics evolved in recent years?
The number of shares of Haemonetics has increased by -0.01% gesunken compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Haemonetics as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Haemonetics?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Haemonetics pay?
Over the past 12 months, Haemonetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Haemonetics is expected to pay a dividend of 0 USD.
What is the dividend yield of Haemonetics?
The current dividend yield of Haemonetics is .
When does Haemonetics pay dividends?
Haemonetics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Haemonetics?
Haemonetics paid dividends every year for the past 0 years.
What is the dividend of Haemonetics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Haemonetics located?
Haemonetics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Haemonetics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Haemonetics from 8/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/10/2024.
When did Haemonetics pay the last dividend?
The last dividend was paid out on 8/10/2024.
What was the dividend of Haemonetics in the year 2023?
In the year 2023, Haemonetics distributed 0 USD as dividends.
In which currency does Haemonetics pay out the dividend?
The dividends of Haemonetics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Haemonetics
Our stock analysis for Haemonetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Haemonetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
